Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05566405
Other study ID # PN 20511/14.10.2020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 27, 2020
Est. completion date September 30, 2022

Study information

Verified date October 2022
Source Sismanoglio General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prostate cancer is one of the most commonly diagnosed neoplasm in men worldwide. The gold standard of therapy is radical prostatectomy, a wide surgical excision of the neoplasm and can be performed either open, laparoscopic or robotic. The open retropubic approach, still performed today, can be completed under either general anaesthesia or combined (spinal/epidural) anaesthesia without any clear guideline on which one should be preferred. In this study the investigators aim to evaluate general anaesthesia and combined (spinal/ epidural) anaesthesia in patients undergoing open retropubic radical prostatectomy and define whether these may have an impact on the oncological outcome and safety of the procedure.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date September 30, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: - Diagnosed with localised prostate cancer - Eligible for open retropubic radical prostatectomy Exclusion Criteria: - Metastatic prostate cancer - History of severe heart disease - History of haemostasis disorders - History of previous pelvic surgery - History of lung disease

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
General Anaesthesia
All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
Combined (Epidural and Spinal) Anaesthesia
Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
Open Retropubic Radical Prostatectomy
All patients will undergo a nerve-sparing open retropubic radical prostatectomy

Locations

Country Name City State
Greece Sismanoglio General Hospital Maroúsi Attiki

Sponsors (2)

Lead Sponsor Collaborator
Sismanoglio General Hospital National and Kapodistrian University of Athens

Country where clinical trial is conducted

Greece, 

References & Publications (8)

Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322-30. — View Citation

Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088. doi: 10.5435/JAAOSGlobal-D-17-00088. eCollection 2018 Mar. — View Citation

Gawande AA, Kwaan MR, Regenbogen SE, Lipsitz SA, Zinner MJ. An Apgar score for surgery. J Am Coll Surg. 2007 Feb;204(2):201-8. Epub 2006 Dec 27. — View Citation

Hatzinger M, Hubmann R, Moll F, Sohn M. [The history of prostate cancer from the beginning to DaVinci]. Aktuelle Urol. 2012 Jul;43(4):228-30. German. — View Citation

Hawthorne G, Sansoni J, Hayes L, Marosszeky N, Sansoni E. Measuring patient satisfaction with health care treatment using the Short Assessment of Patient Satisfaction measure delivered superior and robust satisfaction estimates. J Clin Epidemiol. 2014 May;67(5):527-37. doi: 10.1016/j.jclinepi.2013.12.010. — View Citation

Hinkelbein J, Lamperti M, Akeson J, Santos J, Costa J, De Robertis E, Longrois D, Novak-Jankovic V, Petrini F, Struys MMRF, Veyckemans F, Fuchs-Buder T, Fitzgerald R. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. Eur J Anaesthesiol. 2018 Jan;35(1):6-24. doi: 10.1097/EJA.0000000000000683. Review. — View Citation

Lepor H. A review of surgical techniques for radical prostatectomy. Rev Urol. 2005;7 Suppl 2:S11-7. — View Citation

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Blood Pressure Change Measurement of patients systolic and diastolic blood pressure during the operation and post-operatively for 72 hours. Peri-operatively
Primary Heart Rate Change Measurement of patients Heart Rate during the operation and post-operatively for 72 hours. Peri-operatively
Primary Surgical APGAR Score Calculation of the Surgical APGAR score for each patient during surgery. The lower the score, on a scale of 1-10, the worst the prognosis of the patient.
SAS is calculated using three variables:
Estimated blood loss (on a 0-3 scale, 0 points >1000 ml, 1 point 601-1000ml, 2 points 101-600 ml, 3 points <100ml)
Lowest mean arterial pressure (on a 0-3 scale, 0 points <40 mmHg, 1 point 40-54 mmHg, 2 points 55-69 mmHg, 3 points >70 mmHg)
Lowest heart rate (on a 0-4 scale, 0 points >85 bpm, 1 points 76-85 bpm, 2 points 66-75 bmp, 3 points 56-65 bmp, 4 points <55 bmp) during surgery.
Peri-operatively
Primary Blood Loss During Surgery Measured from suction contents intra-operatively in ml Peri-operatively
Primary Haemoglobin Change Haemoglobin measurement before the operation and at 12-, 24- and 48-hours post-operatively, in g/dL Peri-operatively
Primary Operation Time Time required for:
Induction of anaesthesia
Completion of the operation
Post-operative time until the patient is successfully transferred to the recovery room
Peri-operatively
Primary Pain Assessed by the VAS Scale Measured using a pain Visual Analogue Scale (VAS) at 6-, 24- and 48-hours after the operation.
VAS is a self-reporting pain scale based on a 0 to 10-point system, with each point measuring 10mm on a linear line. Every patient was asked to indicate his pain levels from "No Pain" (equals 0) to "Worst Pain Imaginable" (equals 10).
Peri-operatively
Primary Complication Rate Complications related to the procedure:
Intraoperative bleeding
Post-operative bleeding
Bowel perforation
Cardiovascular
Respiratory
Complications related to the anaesthesia technique performed:
Post-operative headache
Nausea and vomiting
Any signs of potential nerve damage (manifested as inability to gain leg motility)
Peri-operatively and up to 1 year after the operation
Primary Change From Baseline PSA Levels at 6-months Measurement of Prostatic Specific Antigen (PSA) levels at 6 to establish a PSA nadir value 6 months post-operative
Primary Change from 6-month PSA Levels at 12-months Measurement of Prostatic Specific Antigen (PSA) levels at 12 post-operation to detect any biochemical recurrence 12 months post-operative
Secondary Change from Baseline Erectile Function after Radical Prostatectomy Measured using the International Index of Erectile Function (IIEF-5) questionnaires pre-operatively and at 3-, 6- and 12-months post-surgery.
The test is composed of 5 questions with 5 points for each question. Patients are evaluated accordingly:
Score 22 or more = No Erectile Disfunction
Score 17-21 = Mild Erectile Disfunction
Score 12-16 = Mild to moderate Erectile Disfunction
Score 8-11 = Moderate Erectile Disfunction
Score 7 or less = Severe Erectile Disfunction
Results will be:
Analysed and compared to evaluate any potential difference of the two methods of anaesthesia, on post-operational erectile function
Analysed comparing pre-operation with post-operation questioners overall, to evaluate erectile disfunction after radical prostatectomy regardless of method of anaesthesia.
Up to 1 year after the operation
Secondary Post-operative Urinary Incontinence Measured using the International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form at 12 months post-surgery.
The Questionnaire is consisted of 4 questions:
Frequency "How often do you leak urine?" on a scale of 0 (never) to 5 (all the time)
Amount of leakage "How much urine do you leak?" on a scale to 0 (none) to 3 (a large amount)
Overall impact on quality of life "How much does it interfere with your life?" on a scale of 0 (not at all) to 10 (a great deal)
Timing of leakage "When does urine leak?"
1 year after the operation
Secondary Total Hospital Stay Days until patient discharge from the hospital. Peri-operative
Secondary Patient Satisfaction Assessed by the Short Assessment of Patient Satisfaction (SAPS) Questionnaire Satisfaction, using the Short Assessment of Patient Satisfaction (SAPS) Questionnaire, is measured in a scale of 0 to 28, with 0 to 10 equals to "Very Dissatisfied", 11-18 equals to "Dissatisfied", 19-26 equals to "Satisfied" and 27-28 equals to "Very Satisfied" Peri-operative
See also
  Status Clinical Trial Phase
Completed NCT03982095 - Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
Recruiting NCT05667636 - Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP Phase 2
Terminated NCT01996696 - Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate Phase 2
Completed NCT01431391 - Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer Phase 2
Completed NCT03289130 - Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
Recruiting NCT04462926 - Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed N/A
Completed NCT00001446 - A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer Phase 2
Completed NCT02729103 - Treatment Patterns in Metastatic Prostate Cancer N/A
Completed NCT00956228 - Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer Phase 1/Phase 2
Completed NCT00126854 - High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation N/A
Completed NCT00247312 - Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial Phase 3
Completed NCT00174863 - Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer Phase 2
Terminated NCT04221828 - Trial of NanoPac Focal Therapy for Prostate Cancer Phase 2
Completed NCT00001266 - A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma Phase 2
Active, not recruiting NCT03935282 - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors N/A
Completed NCT03693742 - MSG Use With 18F-DCFPyL PET/CT Imaging N/A
Recruiting NCT06236789 - Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
Completed NCT02966535 - The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial N/A
Completed NCT02977143 - Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery N/A
Completed NCT00252460 - CT/MRI Co-registration Prostate Cancer Phase 1